Search

Your search keyword '"Fishman, E.K."' showing total 34 results
Start Over Author "Fishman, E.K." Search Limiters Academic (Peer-Reviewed) Journals
34 results on '"Fishman, E.K."'

18. PET-CT detection of abdominal recurrence of ovarian cancer: radiologic-surgical correlation.

Author

Pannu, H.K., Cohade, C., Bristow, R.E., Fishman, E.K., and Wahl, R.L.

Subjects
OVARIAN cancer, POSITRON emission tomography, TOMOGRAPHY, DIAGNOSTIC imaging, MEDICAL imaging systems, NONINVASIVE diagnostic tests
Abstract

The diagnosis of recurrent ovarian cancer can be difficult on cross-sectional imaging, and variable sensitivities and specificities have been reported for positron emission tomography (PET). Combined functional and anatomic imaging with PET plus computed tomography (CT) potentially allows for improved detection of tumor masses. We investigated the sensitivity, specificity, and accuracy of PET-CT for the diagnosis of recurrent ovarian cancer. Sixteen women with previously treated ovarian cancer underwent imaging on a combined PET-CT scanner followed by surgery to assess for possible recurrent disease. The fused PET-CT images were retrospectively reviewed for recurrent disease, and the results of PET-CT were compared with the operative notes. Eleven of the 16 patients had recurrent disease at surgery. The sensitivity, specificity, and accuracy of PET-CT for disease detection on a per-patient basis were 72.7%, 40%, and 62.5%, respectively. For cases of malignant adenopathy (n = 7), 100% were detected on PET-CT. For peritoneal lesions no larger than 1 cm (n = 23), 13% were detected on PET-CT. For peritoneal lesions larger than 1 cm (n = 8), 50% were detected on PET-CT. The sensitivity of PET-CT for recurrent ovarian cancer is moderate in patients with low volume disease. A trial involving a larger number of patients with a spectrum of disease volumes is necessary to determine the impact of PET-CT in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

27. Vascular reconstruction of locally advanced pancreatic cancer: Tricks of the trade.

Author

van Oosten, A.F., Al Efishat, M., Hasanain, A., Cameron, J.L., Burns, W.R., Burkhart, R.A., Weiss, M.J., Fishman, E.K., Laheru, D., Zheng, L., Narong, A., He, J., and Wolfgang, C.L.

Subjects
*PANCREATIC cancer, *PANCREATECTOMY, *MESENTERIC veins, *HEPATIC artery, *ILIAC artery, *MESENTERIC artery
Abstract

B Presenter: b A. Floortje van Oosten MD | Johns Hopkins University School of Medicine B Background: b Improved systemic and radiation therapies administered as induction therapy have driven a trend of more aggressive operations in patients with locally advanced pancreatic ductal adenocarcinoma (PDAC) that was historically considered technically unresectable. Herein, we present a technical report describing our surgical experience of tumors considered locally advanced with long segment encasement of the superior mesenteric vein (SMV), celiac axis (CA), or the inferior pancreaticoduodenal artery (IPDA) or gastroduodenal artery (GDA) preluding distal pancreatectomy-celiac axis resection (DP-CAR). The option then remains to keep the mesocaval shunt and implant the other branch into the portal vein or to transpose the mesocaval shunt to the portal vein. [Extracted from the article]

Published
2020
Full Text
View/download PDF

30. A Prospective Study Evaluating Stereotactic Body Radiation Therapy in Unresectable Recurrent or Residual Pancreatic Adenocarcinoma.

Author

Assadi, R.K., Rosati, L.M., Moningi, S., Hacker-Prietz, A., Laheru, D.A., Zheng, L., De Jesus-Acosta, A., Le, D.T., Kelly, G., Moore, J., Jackson, J., Fishman, E.K., Raman, S.P., McNutt, T.R., Pawlik, T.M., Hirose, K., Eckhauser, F., Weiss, M.J., and Herman, J.M.

Subjects
*STEREOTACTIC radiotherapy, *PANCREATIC cancer treatment, *ADENOCARCINOMA, *CANCER treatment, *CANCER relapse, *CANCER patients, *PANCREATIC cancer, *LONGITUDINAL method
Published
2015
Full Text
View/download PDF

31. Pathologic Outcomes in Borderline Resectable and Locally Advanced Pancreatic Cancer Patients Receiving Neoadjuvant Stereotactic Body Radiation Therapy.

Author

Rosati, L.M., He, J., Moningi, S., Hacker-Prietz, A., Huebner, T.A., Assadi, R.K., Laheru, D.A., Zheng, L., De Jesus-Acosta, A., Le, D.T., Fishman, E.K., Hruban, R.H., Hirose, K., Makary, M.A., Cameron, J.L., Pawlik, T.M., Wolfgang, C.L., Weiss, M.J., Ellsworth, S.G., and Herman, J.M.

Subjects
*PANCREATIC cancer treatment, *STEREOTACTIC radiotherapy, *ADJUVANT treatment of cancer, *PANCREATIC surgery, *HEALTH outcome assessment
Published
2015
Full Text
View/download PDF

32. Preliminary Results of a Pilot Study Evaluating An Allogeneic GM-CSF Pancreatic Tumor Cell Vaccine (GVAX) and Cytoxan (Cy) With Stereotactic Body Radiation Therapy (SBRT) and Folfirinox (FFX) in Patients With Resected Pancreatic Adenocarcinoma.

Author

Herman, J.M., Parkinson, R., Onners, B., Rao, A.D., Zheng, L., Le, D.T., De Jesus-Acosta, A., Lutz, E., Hruban, R.H., Hirose, K., Fishman, E.K., Weiss, M.J., Hacker-Prietz, A., Pawlik, T.M., Cameron, J.L., Wolfgang, C.L., Jaffee, E.M., and Laheru, D.A.

Subjects
*PANCREATIC tumors, *GRANULOCYTE-macrophage colony-stimulating factor, *GRAFT versus host disease, *CYCLOPHOSPHAMIDE, *ADENOCARCINOMA, *TUMOR treatment
Published
2015
Full Text
View/download PDF

33. Dosimetric Correlations with Toxicity in the First Experience Validating Adjuvant Fractionated Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer.

Author

Rao, A.D., Parkinson, R., Onners, B., Zheng, L., Le, D.T., Lutz, E., De Jesus-Acosta, A., Hruban, R.H., Hirose, K., Fishman, E.K., Weiss, M.J., Hacker-Prietz, A., Pawlik, T.M., Cameron, J.L., Wolfgang, C.L., Jaffee, E.M., Laheru, D.A., and Herman, J.M.

Subjects
*RADIATION dosimetry, *ADJUVANT treatment of cancer, *STEREOTACTIC radiotherapy, *PANCREATIC cancer treatment, *CANCER radiotherapy
Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results